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Background: Xerostomia, a subjective sense of dry mouth, is not generally regarded a disease despite its high
prevalence among the elderly, and therefore continues to impair affected patients’ quality of life. In traditional
Korean medicine, ‘Yin-Deficiency’ has been implicated in the pathogenesis of xerostomia among the elderly.
Yukmijihwang-tang is a famous herbal prescription used to relieve ‘Yin-Deficiency’, and reportedly has antioxidant
effects; therefore, it is postulated that Yukmijihwang-tang can be used to treat xerostomia in the elderly. However,
to our knowledge, no clinical trial has been conducted on the effects of Yukmijihwang-tang on xerostomia. Thus,
we designed a randomized clinical trial to investigate the effects and safety of Yukmijihwang-tang on xerostomia in
the elderly. In addition, we will clarify the aforementioned assumption that ‘Yin-Deficiency’ is the major cause of
xerostomia in the elderly by identifying a correlation between xerostomia and ‘Yin-Deficiency’.
Methods/Design: This randomized, double-blind, placebo-controlled trial will be carried out at two centers: Kyung
Hee University Korean Medicine Hospital and Kyung Hee University Hospital at Gangdong. We will recruit 96
subjects aged 60-80 years who have experienced xerostomia for 3 months prior to participation. Subjects who
present with score >40 on the visual analogue scale for xerostomia and unstimulated salivary flow rate under
0.3mL/min will be included and the randomization will be carried out by an independent statistician by using a
random number creation program. The subjects and all researchers except the statistician will be blinded to the
group assignment. Yukmijihwang-tang or placebo will be administered to each group for 8 weeks. The primary
outcome is change in the scores for the visual analogue scale for xerostomia and the dry mouth symptom
questionnaire from 0 to 8 weeks.
Discussion: It will be assessed whether Yukmijihwang-tang can be used as a new herbal treatment for xerostomia
in the elderly by demonstrating its therapeutic effects in a well-designed clinical trial.
Trial registration: ClinicalTrials.gov Identifier: NCT01579877
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Xerostomia, which is a subjective sense of oral dryness
[1], is a fairly common condition among the elderly [2].
It is estimated that approximately 30% of the population
aged 65 years and older have xerostomia [3], and several
studies have reported a higher prevalence in the elderly
than in the younger population [4-7].
The causes of xerostomia are long-term uses of
xerostomia-inducing medications for chronic diseases and
systemic diseases (for example, Sjögren’s syndrome, diabetes
mellitus, Alzheimer’s disease, and Parkinson’s disease), head
and neck radiation therapy, aging, heavy smoking, and
stress [8]. In the elderly, the long-term use of medications
and aging are regarded as major causes of xerostomia
[9]. However, recent xerostomia studies mostly focused
on Sjögren’s syndrome or postradiotherapy-induced
xerostomia, which are related to salivary gland damage,
and only a few studies have assessed xerostomia in eld-
erly subjects who did not exhibit obvious structural
damage of the salivary glands [10,11].
Xerostomia is not generally accepted as a disease despite
its high prevalence in the elderly; therefore, this condi-
tion continues to impair the affected patient’s quality
of life (QoL) [7,12]. For example, xerostomia in the elderly
is known to cause dental problems and changes in
chewing, swallowing, digestion, and taste [12]. Therefore,
many xerostomia patients turn to solutions such as fre-
quent water intake, sour foods, and alternative therap-
ies (herbs or nutritional supplements) [13]. However, it
is unclear whether these behaviors or therapies provide
relief from xerostomia symptoms.
In traditional Korean medicine (TKM), ‘Yin-Deficiency’
is regarded as the main pathologic cause of xerostomia
in the elderly [14]. Generally, the balance of Yin and
Yang is important for maintaining health and treating
diseases in TKM [14]. Particularly, Yin in ‘Yin-Deficiency’
refers to general body fluids, including blood, and Jing
(mostly translated as ‘essence of body’) [15]. Therefore,
‘Yin-Deficiency’ is closely correlated with a shortage of
body fluids, which results in various symptoms (dry mouth,
dry eyes, or constipation) [14]. TKM has many herbal
prescriptions for treating ‘Yin-Deficiency’ [10,16].
Yukmijihwang-tang (YMJ; Liu-wei-di-huang-tang in trad-
itional Chinese medicine; Lokumijio-to in Kampo Medicine)
is described in the ancient Chinese literature, ‘Key to
Therapeutics of Children’s Diseases’ [17], and is composed
of six herbs. It has long been used for enriching the fluid-
humor of the body in TKM, and it can treat Deficiency
Fire Flaming Upward due to ‘Yin-Deficiency’. Recently,
many studies have described the pharmacological effects of
YMJ, such as protection against renal ischemia/reperfusion
in rats [18], memory enhancement in rats [19], and anti-
oxidant and antidiabetic effects in early diabetic nephrop-
athy patients [20]. In xerostomia-related aspects, YMJ is afamous herbal formula for body enrichment, which
includes relieving ‘Yin-Deficiency’ [21], because of its
demonstrated antioxidant and free radical scavenging
activities in animal studies [18,22]. Thus, it is postu-
lated that YMJ can improve xerostomia in the elderly
by enriching the Qi of the body and tonifying Yin.
However, to our knowledge, no clinical trial has exam-
ined the effects of YMJ on xerostomia. Therefore, we
designed a randomized clinical trial to assess the effects
and safety of the use of YMJ on xerostomia in the elderly.
To evaluate any changes in xerostomia symptoms, the
visual analogue scale (VAS) for xerostomia and the sal-
ivary flow rate will be analyzed.
Methods/Design
Objectives
The aims of this study are to:
(1)obtain clinical evidence regarding the safety and
effects of YMJ in elderly individuals with xerostomia;
(2)identify a correlation between xerostomia in the
elderly and the ‘Yin-deficiency’ state.
Hypothesis
We hypothesize that 8 weeks of YMJ administration will
improve xerostomia in the elderly and will not induce
severe side effects.
Design
This is an academic research study that will be conducted
as a randomized, placebo-controlled, double-blind, two-
center trial at Kyung Hee University Korean Medicine
Hospital and Kyung Hee University Hospital at Gangdong
in Seoul, Korea.
This clinical trial will consist of an 8-week oral admin-
istration of YMJ with two visits at 4-week intervals and a
2-week follow-up period. Before enrollment, all subjects
will go through a 7-day run-in period.
After randomization, all subjects will be divided into two
groups: the YMJ and placebo groups. Each group will be
provided with YMJ or a placebo for 8 weeks and the sub-
jects will be required to take 3 g of YMJ or placebo three
times a day. During the 8-week administration period, sub-
jects will be prohibited from taking any kind of xerostomia-
relieving drug such as pilocarpine or cevimeline. Primary
and secondary outcomes will be measured at baseline and
at 4 weeks, 8 weeks, and 10 weeks after randomization.
The flow of the entire trial is shown in Figure 1.
Sample size calculation
The formula for estimating the sample size is as follows:
nt ¼ nc ¼ Zα=2 þ Zβ
 2
σ2 λþ 1ð Þ=λ
n o
= μc−μtð Þ2
Figure 1 Flow chart of the study.
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ment (μc - μt= Δ) in the VAS for xerostomia after 4 weeks
of treatment compared to that demonstrated after the
placebo treatment [23]. The same study indicated a mean
standard deviation (SD = σ) of 1.87. In our study, the ratio
(λ) of the experimental group to the placebo group will be
1:1. With a power of 80% (1 - β) and a significance level of
5% (α), assuming Δ = 1.54 and σ = 1.87, a sample size
of nt = nc= 36 subjects per each group will be required
(nt, number of YMJ group; nc, number of placebo group).
Considering an assumed dropout rate of 25%, a total of 96
subjects will be needed. Although the intervention period
in this study is different from that in previous similar study,
we chose data from a previous study [23]. The rationale for
choosing these data is the lack of studies or guidelines
that used the same herbal prescription (YMJ) or the
same outcome measure as this study.
On the other hand, to our knowledge, no clinical study
has been conducted to assess the correlation between
xerostomia in the elderly and the ‘Yin-deficiency’ state.
Thus, the current trial is regarded as a pilot study to
assess this correlation. This correlation will be assessed
with a sample size of 96 subjects, which we believe is anappropriate sample size for evaluating this clinical cor-
relation. The results will be shown by using descriptive
statistical analysis.
Inclusion and exclusion criteria
In general, the definition of elderly is used to describe
people over the age of 60 years [24]; in accordance, we
will recruit subjects who are between 60 and 80 years of
age and have experienced xerostomia for 3 months prior
to participation. We have restricted the subjects’ ages to
below 80 years because individuals over this age are con-
sidered to have lower eligibility in this study on the basis
of the rationale that the incidence of disease is increased
as an individual ages.Therefore, we set an upper limit
of 80 years on the subjects’ ages by a consensus among
geriatric disease specialists.
The subjects should present with VAS scores >4 for
xerostomia 2 weeks before the study period. In addition,
the unstimulated salivary flow rates of the subjects should
be under 0.3 mL/min. The subjects must agree that they
will not receive xerostomia-related treatments for 3 months
after initiation of the study.
Subjects who report the following conditions will be
excluded:
(1)a history of treatments for autoimmune diseases like
Sjögren’s syndrome, rheumatism, or lupus;
(2)a history of craniocervical radiation therapy, organ
transplantation, severe psychiatric illness, or major
depression;
(3)the use of any other herbal prescriptions or
nutritional supplements at the screening phase;
(4)the use of xerostomia-relieving medications
(pilocarpine and cevimeline) or therapies for
xerostomia (mouthwash, gum, and toothpaste for
xerostomia).
Recruitment
We will carry out open recruitment by placing adver-
tisements, and the decision to participate will be made
by the subject.
Colored fliers, brochures, and banners will be placed
inside of both hospitals. Furthermore, we will place ad-
vertisements in the newspaper and on the homepage of
the hospitals and the boards of senior welfare centers
around the hospitals.
Randomization
The staff of Hanpoong Pharm & Food Co., Ltd. will first
place a numbered label on each YMJ and placebo according
to the randomization program results provided by the
statistician, and the YMJ and placebo will subsequently
be distributed to each clinical center. The randomization
result table will remain sealed by the statistician.
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independent clinical research coordinator (CRC) will
control randomization. First, the randomization form
containing the basic information of the subject who has
passed the screening phase will be transmitted in facsimile
to an independent statistician. The randomization number
in the randomization form will be left blank before the
statistician receives the form. The statistician will make a
decision about the randomization number based on the
allocation sequence that has been generated by a random
number creation program in advance, and the statistician
will return the randomization form filled in with the
established number (specified ID number) to the CRC.
Then, the clinical pharmacist will distribute the corre-
sponding numbered YMJ or placebo to the subject.
The randomization allocation ratio to the sites will be 1:1.
The CRC will provide the specified ID number to the in-
vestigators. The authorized contract research organization
(CRO) will guarantee that all procedures are performed
correctly.
Blinding
The subjects will be blinded to the treatment that they
receive. Additionally, the investigator, CRC, and clinical
pharmacist will be blinded to the randomization. Only
the independent statistician will be involved in the
randomization, and the entire procedure will be audited
by the authorized CRO (DreamCIS, Seoul, Korea).
Intervention
YMJ
YMJ has long been used in TKM to treat symptoms like
dry mouth or throat, emaciation, decreased urine, an
irritable rash on the palms and soles, insomnia, and
tidal fever caused by ‘Yin-deficiency’ [14]. It is composed
of six herbs: Rehmannia glutinosa, Cornus officinalis,
Dioscorea batatas, Paeonia suffruticosa, Poria cocos, and
Alisma orientale [25].
The YMJ that will be used in this trial is a brown, bitter,
granular, herbal extract (Hexalong granule®, Hanpoong
Pharm & Food Co., Ltd., Jeonju, Korea) produced according
to the Korean Good Manufacturing Practice guidelines.
Hexalong granule® is permitted and regulated by the Korean
Food & Drug Administration. Every 3 g of Hexalong
granule (water-extracted YMJ) includes Rehmannia
glutinosa (2 g), Cornus officinalis (1 g), Dioscorea batatas
(1 g), Paeonia suffruticosa (1 g), Poria cocos (1 g), and
Alisma orientale (1 g) as raw materials.
All herbs will be obtained from qualified suppliers in
Korea, and water-extracted YMJ granules will be sealed
in opaque aluminum bags.
We will administer YMJ to the subjects at a dose of 3 g
according to the specialty publication of the standard guide-
lines of the herbal prescription administration [26].Placebo
Presently, a standard treatment for xerostomia does not
exist. Thus, the placebo YMJ that will be used in this study
does not have active components. The placebo YMJ was
made with cornstarch powder that has the same color and
taste as YMJ by Hanpoong Pharm & Food Co., Ltd. by using
their standard method of placebo manufacturing according
to the Korean Good Manufacturing Practice guidelines. The
placebo YMJ will be packed identically in opaque aluminum
bags with the same labeling form as real YMJ.
Distribution and administration
An independent pharmacist will distribute the experimental
agent packages to the subjects in a separate room and the
CRC will check to ensure that the distribution is correct.
The subjects will be instructed to dissolve the YMJ or
placebo granules from each package in water and take
them 2 h after each meal. Voucher specimens of YMJ will
be retained at the research laboratory of the manufacturer.
The investigator will monitor compliance with the
study treatments by carrying out a telephone conference
once a week between on-site visits. During the telephone
conference, the investigator will inquire how many study
agents the pharmacist has administered and will record
the number on a case report form (CRF). If a subject does
not take all of the YMJ or placebo, they will be asked to re-
turn the unused portion to the CRC at the next visit. The
CRC and clinical pharmacist will double-check and docu-
ment the amount of the returned portions. Finally, clinical
research associates (CRAs) will check compliance with the
study agents at the end of the study.
YMJ and its placebo will be kept and managed by clinical
pharmacists who are independent of the investigators. The
clinical pharmacists will record the date and the number of
study agents during distribution and return.
Outcome measurement
Primary outcome
VAS for xerostomia was chosen as a primary outcome to
evaluate the subject’s improvement regarding discomfort
due to xerostomia (ranging from 0 mm as no xerostomia to
100 mm as the most severe xerostomia). The measurements
of VAS will be carried out at screening, baseline, at 4 weeks,
and 8 weeks during YMJ administration, and at the end of
study (10 weeks after baseline). The change of VAS scores
before and after intervention (from week 0 to week 8) will
be compared between the YMJ and placebo groups.
Secondary outcomes
Dry mouth symptom questionnaire The dry mouth
symptom questionnaire (DMSQ) [27] is composed of six
questions to evaluate subjective oral dryness by using
the VAS and four questions to evaluate behavior to avoid
oral dryness (using the Likert scale). The measurements
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and 10 weeks.
Unstimulated and stimulated salivary flow rate The
unstimulated (USFR) and stimulated salivary flow rate
(SSFR) are secondary outcomes that will be used to
evaluate the effects of YMJ. The overall salivary flow rate
will be determined by the draining method [28]. Briefly,
the subjects will be asked to rest for 10 min before clearing
the mouth by swallowing all saliva within the oral cavity.
Then, they will be instructed to place their tongue above a
graduated cylinder (marked to the nearest 0.1 mL) for 10
min, and the drooled saliva will be collected. After 10 min
of collection, the volume of the collected saliva will be
measured. According to the criteria proposed by Ericsson
and Hardwick [29], hyposalivation will be defined as an
USFR <0.1 mL/min.
Next, the subjects will be asked to chew a paraffin film
(Parafilm: Pechiney Plastic Packaging Company, Chicago,
IL, USA) and the saliva that is induced by chewing will
be collected in a graduated cylinder. After 5 min, the
volume of the saliva will be measured. These measurements
will be carried out at screening, baseline, 4 weeks, 8weeks,
and 10 weeks.
Residual saliva The volume of residual saliva in the sub-
ject’s mouth will be measured to examine the effect of YMJ
on the change in intra-oral saliva. The investigator will
check the volume of residual saliva on the subject’s tongue
and bucca by using the Moisture Checker for Mucus
(MCM: Life Co, Ltd, Tokyo, Japan). This measurement will
be carried out at baseline, 4 weeks, 8 weeks, and 10 weeks.
Salivary immunoglobulin A, salivary chromogranin A,
and salivary cortisol Salivary immunoglobulin (Ig) A,
chromogranin A, and cortisol are well-established biologic
markers of stress in the human body and are associated
with salivary gland secretion [30-34]. These measurements
will be carried out at baseline and at 8 weeks.
In our study, the saliva sample will be collected between
09:00 and 10:00, and the salivary cortisol concentration will
be determined by using the ER HS SALIVARY CORTISOL
kit (Salimetrics, State College, PA, USA). The salivary
Ig A will be examined by using the Salivary Secretory Ig A
indirect enzyme Immunoassay Kit (Salimetrics, State
College, PA, USA). Salivary chromogranin A will be
assessed by using the Chromogranin A (Human) EIA Kit
(Yanaihara, Japan). The analysis will be conducted by using
a microplate reader (Molecular Devices, Sunnyvale, CA,
USA), according to the manufacturer’s instructions.
‘Yin-deficiency’ Questionnaire 1 The development and
validation of the ‘Yin-deficiency’ questionnaire 1 (Yin-DQ1)
was described in a previous study [14]. This questionnaireconsists of 10 VAS-related items: an irritable rash on the
palms or soles, flushing of the zygomatic area in the after-
noon, tidal fever, night sweats, emaciation or weight loss,
dry mouth and/or throat, dizziness, constipation, decreased
urine with yellowish color, and insomnia. The subjects will
take this questionnaire at baseline and 8 weeks.
Safety
We will perform the following tests on all subjects at screen-
ing and after completion of YMJ administration: complete
blood cell count; levels of aspartate aminotransferase/alanine
aminotransferase, gamma-glutamyltranspeptidase, blood
urea nitrogen, and creatinine; and erythrocyte sedimenta-
tion rate. These blood tests will help us to exclude subjects
who have serious diseases and abnormal liver, heart, kidney,
or other organ function. Throughout the present study,
we will also check whether the 8-week administration of
YMJ in xerostomia patients is safe by using these tests
or CRF documentations.
In addition, at each visit, investigators will ask the subjects
whether there are any adverse events (AEs) during the
study period. If there is any AE, the investigator will provide
the appropriate treatment to the subject immediately
and record AEs in the dedicated document of the CRF
including its severity and causality with the experimental
agent. These AEs occurred during the entire study will be
reviewed and monitored by independent CRA.
In the case of serious adverse events (SAEs), the investi-
gator will offer the corresponding treatment to the subject
immediately and report to IRB within 24 h from the time
of recognition. If necessary, blind will be broken by ad-
equate procedure and the documented procedure will
be kept in the investigator study file.
Quality control
To retain the accuracy and quality of the clinical trial,
DreamCIS, an established CRO located in Seoul, Korea,
will audit the study. In addition, regular monitoring will
be implemented by the CRA to ensure that the clinical
trial is proceeding according to the protocol by checking
trial master files, informed consent forms, the CRF, adverse
events, and compliance with study agents.
Statistical analysis
An independent statistician will perform a blind statistical
analysis using SPSS 16.0 (SPSS Inc., Chicago, IL, USA). All
data will be presented as means and SDs, and all analyses
will be based on the intention-to-treat principle.
The analysis strategies in the present study are as follows.
First, we will use the ANCOVA to compare the changes
in VAS scores (primary outcome) to evaluate the effects of
YMJ and the placebo from the beginning (0 week) to the
end (8 weeks) of the study period. Second, the secondary
outcomes (DMSQ scores, USFR, SSFR, volume of residual
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deficiency’ score) will be analyzed in the same manner as
the primary outcome. Finally, correlation between subjective
(VAS and DMSQ) and objective xerostomia-related
variables (USFR, SSFR, and residual saliva) will be analyzed
by Pearson’s correlation coefficients. Also, we will find
out how xerostomia-related variables correlate with
‘Yin-deficiency’ score or stress-related variables (salivary
Ig A, chromogranin A, and cortisol), respectively, using
Pearson’s correlation coefficients. In addition, we will check
the AEs in YMJ and placebo group each and describe them
using the descriptive statistics.
Ethical approval and registration
This study will be carried out in accordance with the stan-
dards of the International Committee on Harmonization
on Good Clinical Practice and the revised version of the
Declaration of Helsinki. The protocol of the trial has been
approved by two ethics committees: the Institutional
Review Boards (IRBs) of both the Oriental Hospital at
Kyung Hee University Medical Center and the Kyung
Hee University Hospital at Gangdong. The permission
numbers are KOMCIRB 2011-28 for the Oriental Hospital
at Kyung Hee University Medical Center and KHNMC-
OH-IRB 2011-016 for the Kyung Hee University Hospital
at Gangdong.
The process of obtaining consent will be carried out
by the principle of informed consent, which consists of
information, decisional capacity, and voluntarism. Prior
to screening, written informed consent approved by
the IRB will be obtained from all participants who
present at a clinic in response to an advertisement.
The investigator will explain the study by using non-
scientific language before the subjects read the terms
of consent. Subjects will be given adequate time to decide
whether they wish to participate before signing the
consent form. After this process, if the subject spon-
taneously wishes to participate in the study, they will
sign the consent form.
This trial is registered with the ClinicalTrials.gov protocol
registration system, ID NCT01579877.
Discussion
This clinical trial, which will be conducted as one of the
nationwide projects to provide scientific evidence for
TKM, belongs to the 2011 Traditional Korean Medicine
R&D projects funded by the Ministry for Health & Welfare
& Family Affairs, Republic of Korea.
The present study emphasizes the significance of
treatment for xerostomia in the elderly, which has been
neglected clinically up to this point, and can play an
important role in giving prominence to treatment for
this condition. We anticipate that this study will reveal
that a herbal prescription and a typical TKM treatmentmethod, YMJ, can be an alternative treatment for
xerostomia in the elderly, a condition that presently
has no suitable remedy.
In general, herbal medicine is a key tool of TKM treat-
ment and is known to have a great curative power for
many diseases [35,36]. YMJ, which is one of the most
frequently used herbal formulas in Korea, is regarded to
be safe and to have a beneficial effect on xerostomia in the
elderly [21]. However, to our knowledge, no randomized
controlled trials have shown the effectiveness of YMJ for
xerostomia. Therefore, the current study was designed to
obtain objective clinical evidence on the effects and safety
of YMJ for the treatment of xerostomia in the elderly.
If the effects of YMJ are verified in the present study, it
could be used as a new alternative treatment option by
elderly individuals with xerostomia, which is highly
prevalent and without established standard therapies in
conventional medicine.
The current study has three potential strengths. First,
it is unique because the subjects of this study will have
general xerostomia without the structural damage to the
salivary glands that occurs with autoimmune disease or a
history of radiation. Second, the ‘Yin-deficiency’ question-
naire, an indigenous pattern identification tool in TKM, will
be applied to diagnose the subjects’ xerostomia according
to TKM theory. If a high correlation is found between
xerostomia in the elderly and ‘Yin-deficiency’, this will
provide reasonable evidence for prescribing YMJ for
xerostomia in the elderly. Third, we will determine
whether YMJ can change the subjective feeling of dry
mouth as well as the salivary flow rate. Although the
relationship between a subjective feeling of dry mouth
and the salivary flow rate is controversial [8,9,37], the
change in these factors in association with YMJ treat-
ment could be compared in this study.Trial status
This study is currently recruiting patients.
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